Schistosomiasis is a worldwide
parasitic disease, and while it can be successfully treated with
chemotherapy, this does not prevent
reinfection with the parasite. Adenovirus vectors have been widely used for
vaccine delivery, and a vaccination approach has the potential to prevent
infection with Schistosoma. Here, we developed a recombinant adenoviral vector that expresses Schistosoma japonicum inhibitor apoptosis
protein (Ad-SjIAP) and assessed its immunoprotective functions against
schistosomiasis in mice. Murine immune responses following vaccination were investigated using
enzyme-linked
immunosorbent assays (ELISA), lymphocyte proliferation, and
cytokine assays. The protective immunity in mice was evaluated by challenging with S. japonicum cercariae. Our results indicated that immunization with the Ad-SjIAP in mice induced a strong serum
IgG response against IAP including
IgG1,
IgG2a, and
IgG2b. In addition, lymphocyte proliferation experiments showed that mice treated with Ad-SjIAP significantly increased the lymphocyte response upon stimulation with recombinant Schistosoma japonicum inhibitor apoptosis
protein (rSjIAP). Moreover,
cytokine assays indicated that vaccination of Ad-SjIAP significantly increased the production of
interferon (IFN)-γ and
IL-2 as compared to the corresponding control group. Furthermore, following the challenge with S. japonicum cercariae, the
vaccine conferred moderate protection, with an average rate of 37.95% for worm reduction and 31.7% for egg reduction. Taken together, our preliminarily results suggested that schistosoma IAP may be a potential
vaccine against S. japonicum and that adenoviral vectors may serve as an alternative delivery vehicle for schistosome
vaccine development.